AMNEAL PHARMACEUTICALS INC (AMRX)

US03168L1052 - Common Stock

6.14  +0.02 (+0.33%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (3/28/2024, 2:15:35 PM)

6.14

+0.02 (+0.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.88B
Shares
PE9.59
Fwd PE10.34
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMRX Daily chart

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 7,600 full-time employees. The company went IPO on 2009-11-18. The firm is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The firm's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Company Info

AMNEAL PHARMACEUTICALS INC

400 Crossing Boulevard, 3rd Floor

Bridgewater NEW JERSEY 08807

P: 19089473120

CEO: Chirag Patel

Employees: 7600

Website: https://amneal.com/

AMRX News

News Image3 days ago - Amneal Pharmaceuticals, Inc.Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!

News Imagea month ago - Seeking AlphaAmneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $617M misses by $17.86M (NASDAQ:AMRX)

Amneal Pharmaceuticals reports Q4 earnings, beating earnings per share estimates but missing revenue expectations.

News Imagea month ago - Amneal Pharmaceuticals, Inc.Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
News Imagea month ago - Amneal Pharmaceuticals, Inc.Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
News Imagea month ago - Amneal Pharmaceuticals, Inc.Amneal to Participate at Upcoming Investor Conference

AMRX Twits

Here you can normally see the latest stock twits on AMRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example